Clinical Trials Directory

Trials / Available

AvailableNCT06362590

Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors

Status
Available
Phase
Study type
Expanded Access
Enrollment
Sponsor
Seagen Inc. · Industry
Sex
Age
Healthy volunteers

Summary

The purpose of this study is to provide the option of Ladiratuzumab Vedotin treatment to eligible patients in studies SGNLVA-005.

Interventions

TypeNameDescription
DRUGladiratuzumab vedotin

Timeline

First posted
2024-04-12
Last updated
2025-06-17

Source: ClinicalTrials.gov record NCT06362590. Inclusion in this directory is not an endorsement.

Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors (NCT06362590) · Clinical Trials Directory